Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis

Fig. 1

Evidence for AC092894.1 being downregulated in oxaliplatin-resistant CRC cells. A LoVo and LoVo-OxR cells were treated with high concentrations of oxaliplatin for 48 h to determine cell viability. B Volcano plot showing differentially expressed lncRNAs in LoVo and LoVo-OxR cells. C RT-qPCR assays for the expression of the top two most downregulated lncRNAs. D Expression of AC092894.1 in our cohort of CRC patients sensitive (n = 28) and resistant (n = 22) to oxaliplatin treatment. E Progression-free survival was analyzed using survival curves. F, G Microscopic photographs of organs and RT-qPCR detection of AC092894.1 expression in organoids treated with 5 μg/ml oxaliplatin for 72 h. H After treatment with the indicated concentrations of oxaliplatin for 48 h, the cell viability of different CRC cells was detected by CCK-8. I RT-qPCR assay to detect the expression of AC092894.1 in different CRC cells

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us